Literature DB >> 22781594

Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS.

J A Katzmann1, R Clark, R A Kyle, D R Larson, T M Therneau, L J Melton, J T Benson, C L Colby, A Dispenzieri, O Landgren, S Kumar, A R Bradwell, J R Cerhan, S V Rajkumar.   

Abstract

We hypothesized that the suppression of uninvolved immunoglobulin in monoclonal gammopathy of undetermined significance (MGUS) as detected by suppression of the isotype-specific heavy and light chain (HLC-pair suppression) increases the risk of progression to malignancy. This approach required quantitation of individual heavy/light chains (for example, IgGλ in IgGκ MGUS patients). Of 1384 MGUS patients from Southeastern Minnesota seen at the Mayo Clinic from 1960 to 1994, baseline serum samples obtained within 30 days of diagnosis were available in 999 persons. We identified HLC-pair suppression in 27% of MGUS patient samples compared with 11% of patients with suppression of uninvolved IgG, IgA or IgM. HLC-pair suppression was a significant risk factor for progression (hazard ratio (HR), 2.3; 95% confidence interval (CI) 1.5-3.7; P<0.001). On multivariate analysis, HLC-pair suppression was an independent risk factor for progression to malignancy in combination with serum M-spike size, heavy chain isotype and free light chain ratio (HR, 1.8; 95% CI, 1.1-3.00; P=0.018). The finding that HLC-pair suppression predicts progression in MGUS and occurs several years before malignant transformation has implications for myeloma biology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22781594      PMCID: PMC3691011          DOI: 10.1038/leu.2012.189

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  14 in total

Review 1.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Authors:  T A Gooley; W Leisenring; J Crowley; B E Storer
Journal:  Stat Med       Date:  1999-03-30       Impact factor: 2.373

2.  Prevalence of monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Dirk R Larson; Matthew F Plevak; Janice R Offord; Angela Dispenzieri; Jerry A Katzmann; L Joseph Melton
Journal:  N Engl J Med       Date:  2006-03-30       Impact factor: 91.245

3.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton
Journal:  N Engl J Med       Date:  2002-02-21       Impact factor: 91.245

4.  Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance.

Authors:  S Vincent Rajkumar; Robert A Kyle; Terry M Therneau; L Joseph Melton; Arthur R Bradwell; Raynell J Clark; Dirk R Larson; Matthew F Plevak; Angela Dispenzieri; Jerry A Katzmann
Journal:  Blood       Date:  2005-04-26       Impact factor: 22.113

5.  Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications.

Authors:  Giada Bianchi; Robert A Kyle; Colin L Colby; Dirk R Larson; Shaji Kumar; Jerry A Katzmann; Angela Dispenzieri; Terry M Therneau; James R Cerhan; L Joseph Melton; S Vincent Rajkumar
Journal:  Blood       Date:  2010-05-21       Impact factor: 22.113

6.  Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

Authors:  Clara Cesana; Catherine Klersy; Luciana Barbarano; Anna Maria Nosari; Monica Crugnola; Ester Pungolino; Livio Gargantini; Simonetta Granata; Marina Valentini; Enrica Morra
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

Review 7.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.

Authors:  R A Kyle; B G M Durie; S V Rajkumar; O Landgren; J Blade; G Merlini; N Kröger; H Einsele; D H Vesole; M Dimopoulos; J San Miguel; H Avet-Loiseau; R Hajek; W M Chen; K C Anderson; H Ludwig; P Sonneveld; S Pavlovsky; A Palumbo; P G Richardson; B Barlogie; P Greipp; R Vescio; I Turesson; J Westin; M Boccadoro
Journal:  Leukemia       Date:  2010-04-22       Impact factor: 11.528

8.  New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.

Authors:  Ernesto Pérez-Persona; María-Belén Vidriales; Gema Mateo; Ramón García-Sanz; Maria-Victoria Mateos; Alfonso García de Coca; Josefina Galende; Guillermo Martín-Nuñez; José M Alonso; Natalia de Las Heras; José M Hernández; Alejandro Martín; Consuelo López-Berges; Alberto Orfao; Jesús F San Miguel
Journal:  Blood       Date:  2007-06-18       Impact factor: 22.113

9.  Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans.

Authors:  E Sally Ward; Jinchun Zhou; Victor Ghetie; Raimund J Ober
Journal:  Int Immunol       Date:  2003-02       Impact factor: 4.823

10.  Monoclonal gammopathy of undetermined significance. Natural history in 241 cases.

Authors:  R A Kyle
Journal:  Am J Med       Date:  1978-05       Impact factor: 4.965

View more
  29 in total

Review 1.  The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.

Authors:  Niels W C J van de Donk; Antonio Palumbo; Hans Erik Johnsen; Monika Engelhardt; Francesca Gay; Henrik Gregersen; Roman Hajek; Martina Kleber; Heinz Ludwig; Gareth Morgan; Pellegrino Musto; Torben Plesner; Orhan Sezer; Evangelos Terpos; Anders Waage; Sonja Zweegman; Hermann Einsele; Pieter Sonneveld; Henk M Lokhorst
Journal:  Haematologica       Date:  2014-03-21       Impact factor: 9.941

2.  CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease.

Authors:  Sarah K Johnson; James P Stewart; Rakesh Bam; Pingping Qu; Bart Barlogie; Frits van Rhee; John D Shaughnessy; Joshua Epstein; Shmuel Yaccoby
Journal:  Blood       Date:  2014-07-24       Impact factor: 22.113

3.  Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: new criteria for differential diagnosis and risk stratification.

Authors:  B Paiva; M C Montes; R García-Sanz; E M Ocio; J Alonso; N de Las Heras; F Escalante; R Cuello; A G de Coca; J Galende; J Hernández; M Sierra; A Martin; E Pardal; A Bárez; J Alonso; L Suarez; T J González-López; J J Perez; A Orfao; M-B Vidríales; J F San Miguel
Journal:  Leukemia       Date:  2013-04-22       Impact factor: 11.528

4.  Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma.

Authors:  E Kastritis; F Zagouri; A Symeonidis; M Roussou; A Sioni; A Pouli; S Delimpasi; E Katodritou; E Michalis; M Michael; E Hatzimichael; A Vassou; P Repousis; A Christophoridou; Z Kartasis; E Stefanoudaki; C Megalakaki; S Giannouli; M-C Kyrtsonis; K Konstantopoulos; M Spyroupoulou-Vlachou; E Terpos; M A Dimopoulos
Journal:  Leukemia       Date:  2014-03-18       Impact factor: 11.528

Review 5.  Novel Immunotherapies for Multiple Myeloma.

Authors:  Mattia D'Agostino; Mario Boccadoro; Eric L Smith
Journal:  Curr Hematol Malig Rep       Date:  2017-08       Impact factor: 3.952

6.  Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication.

Authors:  A Arteche-López; A Kreutzman; A Alegre; P Sanz Martín; B Aguado; M González-Pardo; M Espiño; L M Villar; D García Belmonte; R de la Cámara; C Muñoz-Calleja
Journal:  Bone Marrow Transplant       Date:  2017-04-03       Impact factor: 5.483

Review 7.  Evolutionary biology of high-risk multiple myeloma.

Authors:  Charlotte Pawlyn; Gareth J Morgan
Journal:  Nat Rev Cancer       Date:  2017-08-24       Impact factor: 60.716

8.  Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis.

Authors:  Ronald S Go; Jacob D Gundrum; Joan M Neuner
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-09-28

Review 9.  Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.

Authors:  Amit Agarwal; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2012-12-05       Impact factor: 12.531

10.  Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study.

Authors:  Anita D'Souza; Marcelo Pasquini; Brent Logan; Sergio Giralt; Amrita Krishnan; Joseph Antin; Alan Howard; Stacy Goodman; Muzzafar Qazilbash; Kristin Knust; Firoozeh Sahebi; Daniel Weisdorf; David Vesole; Edward Stadtmauer; David Maloney; Parameswaran Hari
Journal:  Br J Haematol       Date:  2016-06-13       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.